A review of phosphodiesterase type 5 inhibitors

Keyphrases

• Cardiac Hypertrophy 50%
• Clinical Application 50%
• Erectile Dysfunction 50%
• Heart Failure 50%
• Hypertension 50%
• Ischemia Injury 50%
• Ischemia-reperfusion Injury 50%
• Mechanism of Action 50%
• Myocardial Infarction 50%
• PDE Inhibitors 50%
• Pharmacokinetics 50%
• Phosphodiesterase Type 5 Inhibitors 100%
• Pulmonary Hypertension Treatment 50%
• Raynaud's Phenomenon 50%
• Sildenafil 100%
• South Africa 50%
• Tadalafil 50%
• Vardenafil 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 50%
• Erectile Dysfunction 50%
• Heart Infarction 50%
• Heart Ventricle Hypertrophy 50%
• Ischemia 50%
• Pharmacokinetics 50%
• Phosphodiesterase V Inhibitor 100%
• Pulmonary Hypertension 50%
• Raynaud Phenomenon 50%
• Reperfusion Injury 50%
• Side Effect 50%
• Sildenafil 100%
• Tadalafil 50%
• Vardenafil 50%

Medicine and Dentistry

• Congestive Heart Failure 50%
• Erectile Dysfunction 50%
• Ischemia 50%
• Myocardial Infarction 50%
• Pharmacokinetics 50%
• Phosphodiesterase V Inhibitor 100%
• Pulmonary Hypertension 50%
• Raynaud Phenomenon 50%
• Reperfusion Injury 50%
• Side Effect 50%
• Sildenafil 100%
• Tadalafil 50%
• Vardenafil 50%
• Ventricular Hypertrophy 50%